Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years

Journal of Crohn's and Colitis

Volumn 2, Issue 2, 2008, Pages 114-122

  Høie, Ole ^a   Aamodt, Geir ^b   Vermeire, Severine ^c   Bernklev, Tomm ^j   Odes, Selwyn ^d   Wolters, Frank L ^e   Riis, Lene ^f   Politi, Patrizia ^g   Tsianos, Epameinondas V ^h   Butrón, Mercedes ⁱ   Stockbrügger, Reinhold W ^e   Munkholm, Pia ^f   Vatn, Morten ^b   Moum, Bjørn ^j  

^a Sørlandet Hospital   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UZ Gasthuisburg ^*  (Belgium)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g CREMONA HOSPITAL   (Italy)

^h UNIVERSITY OF IOANNINA   (Greece)

ⁱ University Hospital of Vigo   (Spain)

^j AKER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Disease course; Inception cohort; Population based; Serological markers; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; FUNGUS ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLON RESECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FAMILIAL DISEASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; RESIDENTIAL AREA; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

EID: 43449118677     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2007.10.001     Document Type: Article

References (35)

1. Nakamura R.M., Matsutani M., and Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta 335 1-2 (2003) 9-20
2. Sandborn W.J., Loftus Jr. E.V., Colombel J.F., et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 7 3 (2001) 192-201
3. Stockbrugger R.W., Russel M.G., van Blankenstein M., et al. EC-IBD: a European effort in inflammatory bowel disease. Eur J Intern Med 11 4 (2000) 187-190
4. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 170 (1989) 2-6 Suppl
5. Shivananda S., Lennard-Jones J., Logan R., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39 5 (1996) 690-697
6. Wolters F.L., van Zeijl G., Sijbrandij J., et al. Internet-based data inclusion in a population-based European collaborative follow-up study of inflammatory bowel disease patients: description of methods used and analysis of factors influencing response rates. World J Gastroenterol 11 45 (2005) 7152-7158
7. Vermeire S., Joossens S., Peeters M., et al. Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 120 4 (2001) 827-833
8. Peeters M., Joossens S., Vermeire S., et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 96 3 (2001) 730-734
9. Roozendaal C., and Kallenberg C.G. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?. Clin Exp Immunol 116 2 (1999) 206-213
10. Gigase P., De Clerck L.S., Van Cotthem K.A., et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies. Dig Dis Sci 42 10 (1997) 2171-2174
11. Sandborn W.J. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord 4 4 (2004) 167-174
12. Sandborn W.J., Landers C.J., Tremaine W.J., et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 71 5 (1996) 431-436
13. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49 5 (2001) 671-677
14. Kuisma J., Jarvinen H., Kahri A., et al. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 39 6 (2004) 544-548
15. Reumaux D., Colombel J.F., Masy E., et al. Anti-neutrophil cytoplasmic auto-antibodies (ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflamm Bowel Dis 6 4 (2000) 270-274
16. Roozendaal C., Pogany K., Hummel E.J., et al. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. QJM 92 11 (1999) 651-658
17. Zholudev A., Zurakowski D., Young W., et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 99 11 (2004) 2235-2241
18. Lindgren S., Floren C.H., Lindhagen T., et al. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission. Eur J Gastroenterol Hepatol 7 6 (1995) 563-568
19. Rump J.A., Worner I., Roth M., et al. p-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity and therapy. Adv Exp Med Biol 336 (1993) 507-513
20. Vecchi M., Bianchi M.B., Calabresi C., et al. Long-term observation of the perinuclear anti-neutrophil cytoplasmic antibody status in ulcerative colitis patients. Scand J Gastroenterol 33 2 (1998) 170-173
21. Hoie O., Wolters F.L., Riis L., et al. Low colectomy rates in ulcerative colitis in a European cohort followed for ten years. Gastroenterology 132 2 (2007) 507-515
22. Hoie O., Wolters F.L., Riis L., et al. Ulcerative Colitis: Patient characteristics may predict 10-year disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 102 (2007) 1692-1701
23. Targan S.R., Landers C.J., Cobb L., et al. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol 155 6 (1995) 3262-3267
24. Langholz E., Munkholm P., Davidsen M., et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 1 (1994) 3-11
25. Vasiliauskas E.A., Plevy S.E., Landers C.J., et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 110 6 (1996) 1810-1819
26. Walker L.J., Aldhous M.C., Drummond H.E., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 135 3 (2004) 490-496
27. Odes S., Friger M., Vardi H., et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a Project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm Bowel Dis 13 7 (2007) 874-881
28. Birrenbach T., and Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 10 6 (2004) 848-859
29. Bresci G., Parisi G., Bertoni M., et al. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig Liver Dis 34 6 (2002) 419-423
30. Edwards F.C., and Truelove S.C. The course and prognosis of ulcerative colitis. Gut 41 (1963) 299-315
31. Oudkerk P.M., Ellerbroek P.M., Ridwan B.U., et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 34 1 (1993) 46-50
32. Teml A., Kratzer V., Schneider B., et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 98 10 (2003) 2226-2231
33. Muller S., Styner M., Seibold-Schmid B., et al. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J Gastroenterol 11 44 (2005) 6988-6994
34. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54 9 (2005) 1232-1236
35. Nielsen O.H., Vainer B., Madsen S.M., et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 95 2 (2000) 359-367